EZH2 inhibitors are reported to exert therapeutic effects on various kidney diseases, including renal cell carcinoma, AKI, renal fibrosis, diabetic nephropathy, lupus nephritis, and renal transplant rejection [19, 20]. The gene discussed is EZH2; the disease is renal fibrosis.